Albany Molecular Research Inc (AMRI)

13.72
0.08 0.58
NASDAQ : Health Care
Prev Close 13.80
Open 13.79
Day Low/High 13.58 / 13.85
52 Wk Low/High 12.45 / 22.48
Volume 362.07K
Avg Volume 289.20K
Exchange NASDAQ
Shares Outstanding 35.70M
Market Cap 511.63M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AMRI: Insiders vs. Shorts

AMRI: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Albany Molecular Research Inc is one of the most shorted stocks of the Russell 3000, based on 20.08 "days to cover" versus the median component at 6.16. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

AMRI Clarifies 2016 Revenue Guidance

AMRI Clarifies 2016 Revenue Guidance

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a weak on high relative volume candidate

Commit To Buy Albany Molecular Research At $12.50, Earn 13.3% Annualized Using Options

Commit To Buy Albany Molecular Research At $12.50, Earn 13.3% Annualized Using Options

Investors considering a purchase of Albany Molecular Research, Inc. shares, but tentative about paying the going market price of $14.70/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Albany Molecular Research Enters Oversold Territory (AMRI)

Albany Molecular Research Enters Oversold Territory (AMRI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AMRI Appoints Anthony J. Maddaluna To Board Of Directors

AMRI Appoints Anthony J. Maddaluna To Board Of Directors

- Pfizer Executive Brings Additional Pharmaceutical Industry Experience and Expertise to the Board -

AMRI And NYCNMR Form Collaborative Agreement

AMRI And NYCNMR Form Collaborative Agreement

Collaboration to Enhance Application of Nanotechnology in Integrated Drug Discovery Setting

Eagle Pharmaceuticals And AMRI Announce Agreement To Jointly Develop, Manufacture And Commercialize Parenteral Drug Products

Eagle Pharmaceuticals And AMRI Announce Agreement To Jointly Develop, Manufacture And Commercialize Parenteral Drug Products

Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ:EGRX) and AMRI (NASDAQ:AMRI) today announced that they have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug...

AMRI Announces First Product Approval Out Of Its Massachusetts Aseptic Fill Finish Site

AMRI Announces First Product Approval Out Of Its Massachusetts Aseptic Fill Finish Site

First Alcohol-Free Formulation Provides U.S. Patients with Alternative to Traditional Docetaxel Injection Treatment

Oversold Conditions For Albany Molecular Research (AMRI)

Oversold Conditions For Albany Molecular Research (AMRI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AMRI And Icagen Ink Collaboration Agreement

AMRI And Icagen Ink Collaboration Agreement

Collaboration to Provide Drug Discovery Customers with Industry Leading Ion Channel and Transporter Capabilities

AMRI Acquires Whitehouse Laboratories

AMRI Acquires Whitehouse Laboratories

-- Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services

AMRI And Multispan Ink Collaboration Agreement

AMRI And Multispan Ink Collaboration Agreement

Collaboration to Provide Broad Industry Access to Next-Generation Drug Discovery GPCR Technologies for Enhanced Customer Success